NCT00613054: Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent Malignant Glioma |
|
|
| Completed | 1 | 27 | US | Zactima, Gleevec, Hydroxyurea, Zactima-ZD6474-Vandetanib, Gleevec-Imatinib mesylate, Hydroxyurea-Droxia-Hydrea-Hydroxycarbamide | Annick Desjardins, Novartis Pharmaceuticals, AstraZeneca | Glioblastoma, Gliosarcoma | 03/09 | 04/09 | | |
NCT00613223: Ph I Dose Escalation Trial of Vandetanib in Combo w Etoposide for Malignant Gliomas |
|
|
| Completed | 1 | 49 | US | Vandetanib and Etoposide, Vandetanib - Zactima (ZD 6474), Etoposide - VP-16, Etopophos, Toposar, VePesid | Annick Desjardins, AstraZeneca | Gliosarcoma, Glioblastoma | 10/10 | 05/11 | | |